文献速递肝病

肝脏RGS5通过抑制TAK1-JNK/p38信号改善非酒精性脂肪性肝病

Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta-Activated Kinase 1-c-Jun-N-Terminal Kinase/p38 Signaling.
PubMed 文献 · Hepatology · 2020-11-07

该研究结合基因工程啮齿动物模型与转录组测序,探讨RGS5在NAFLD发生发展中的作用及调控机制。研究发现RGS5保护小鼠抵抗NAFLD和非酒精性脂肪性肝炎,其机制为RGS5直接结合TAK1并抑制TAK1磷酸化及下游JNK/p38通路激活。RGS5是调控TAK1活性及治疗NAFLD的潜在靶点。

要点

  • RGS5在肝脏中保护小鼠抵抗NAFLD和NASH进展。
  • RGS5通过其64-181氨基酸片段直接结合TAK1的1-300氨基酸片段。
  • RGS5抑制TAK1磷酸化及下游JNK/p38信号级联激活。

核心结论

  • 在肝细胞中,RGS5是保护抵抗NAFLD进展的关键分子。
  • RGS5直接结合TAK1,阻止其过度磷酸化及下游JNK/p38信号级联激活。
  • RGS5是精细调控TAK1活性及治疗NAFLD的有前景的靶点分子。

研究设计与样本

  • 研究结合基因工程啮齿动物模型与转录组测序方法。
  • 采用RNA测序及无偏系统研究策略探究RGS5在NAFLD中的作用与调控机制。

主要发现

  • RGS5保护小鼠抵抗NAFLD和非酒精性脂肪性肝炎。
  • 代谢挑战下MAPK信号级联的激活与肝脏RGS5表达呈负相关。
  • RGS5的64-181氨基酸片段通过TAK1的1-300氨基酸片段直接相互作用。
  • RGS5抑制TAK1磷酸化及后续JNK/p38通路激活。

临床怎么用

  • RGS5可作为精细调控TAK1活性的潜在靶点。
  • RGS5为NAFLD治疗提供了有前景的靶点分子方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, which has no specific pharmacological treatments partially because of the unclear pathophysiological mechanisms. Regulator of G protein signaling (RGSs) proteins are proteins that negatively regulate G protein-coupled receptor (GPCR) signaling. The members of the R4/B subfamily are the smallest RGS proteins in size, and RGS5 belongs to this family, which mediates pluripotent biological functions through canonical G protein-mediated pathways and non-GPCR pathways. This study combined a genetically engineered rodent model and a transcriptomics-sequencing approach to investigate the role and regulatory mechanism of RGS5 in the development of NAFLD. APPROACH AND RESULTS: This study found that RGS5 protects against NAFLD and nonalcoholic steatohepatitis. Using RNA sequencing and an unbiased systematic investigative approach, this study found that the activation of mitogen-activated protein kinase signaling cascades in response to metabolic challenge is negatively associated with hepatic RGS5 expression. Mechanistically, we found that the 64-181 amino-acid-sequence (aa) fragment of RGS5 directly interacts with transforming growth factor beta-activated kinase 1 (TAK1) through the 1-300aa fragment and inhibits TAK1 phosphorylation and the subsequent c-Jun-N-terminal kinase (JNK)/p38 pathway activation. CONCLUSIONS: In hepatocytes, RGS5 is an essential molecule that protects against the progression of NAFLD. RGS5 directly binds to TAK1, preventing its hyperphosphorylation and the activation of the downstream JNK/p38 signaling cascade. RGS5 is a promising target molecule for fine-tuning the activity of TAK1 and for the treatment of NAFLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wang J, Ma J, Nie H, et al. Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta-Activated Kinase 1-c-Jun-N-Terminal Kinase/p38 Signaling. Hepatology. 2020. PMID: 32191345. doi:10.1002/hep.31242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。